As of 2025-07-12, the Relative Valuation of Pacira Biosciences Inc (PCRX) is (32.95) USD. This relative valuation is based on P/E multiples. With the latest stock price at 22.90 USD, the upside of Pacira Biosciences Inc based on Relative Valuation is -243.9%.
The range of the Relative Valuation is (29.88) - (37.04) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 21.9x | 16.2x |
| Forward P/E multiples | 14.5x - 18.1x | 16.0x |
| Fair Price | (29.88) - (37.04) | (32.95) |
| Upside | -230.5% - -261.7% | -243.9% |
| Date | P/E |
| 2025-07-10 | -11.58 |
| 2025-07-09 | -11.32 |
| 2025-07-08 | -11.33 |
| 2025-07-07 | -11.35 |
| 2025-07-03 | -11.35 |
| 2025-07-02 | -11.34 |
| 2025-07-01 | -11.36 |
| 2025-06-30 | -11.68 |
| 2025-06-27 | -11.47 |
| 2025-06-26 | -11.59 |
| 2025-06-25 | -11.68 |
| 2025-06-24 | -12.03 |
| 2025-06-23 | -12.09 |
| 2025-06-20 | -11.84 |
| 2025-06-18 | -11.80 |
| 2025-06-17 | -11.92 |
| 2025-06-16 | -11.89 |
| 2025-06-13 | -11.85 |
| 2025-06-12 | -11.95 |
| 2025-06-11 | -11.89 |
| 2025-06-10 | -12.15 |
| 2025-06-09 | -12.42 |
| 2025-06-06 | -12.69 |
| 2025-06-05 | -13.07 |
| 2025-06-04 | -13.18 |
| 2025-06-03 | -12.90 |
| 2025-06-02 | -12.82 |
| 2025-05-30 | -12.63 |
| 2025-05-29 | -12.67 |
| 2025-05-28 | -12.49 |
| 2025-05-27 | -12.62 |
| 2025-05-23 | -12.58 |
| 2025-05-22 | -12.74 |
| 2025-05-21 | -12.77 |
| 2025-05-20 | -13.07 |
| 2025-05-19 | -12.78 |
| 2025-05-16 | -12.64 |
| 2025-05-15 | -12.51 |
| 2025-05-14 | -11.95 |
| 2025-05-13 | -11.43 |
| 2025-05-12 | -12.26 |
| 2025-05-09 | -12.28 |
| 2025-05-08 | -12.17 |
| 2025-05-07 | -12.30 |
| 2025-05-06 | -12.29 |
| 2025-05-05 | -12.61 |
| 2025-05-02 | -12.93 |
| 2025-05-01 | -13.07 |
| 2025-04-30 | -13.15 |
| 2025-04-29 | -13.19 |